Epcoritamab + R-2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.Reid Merryman,David Belada,Anna Sureda,Sirpa Leppa,Joost S. P. Vermaat,Harald Holte,Martin Hutchings,Pieternella Lugtenburg,Sven de Vos,Pau Abrisqueta,Marcel Nijland,Jacob Haaber Christensen,Bjorn E. Wahlin,Kim M. Linton,Liwei Wang,Aqeel Abbas,Ali Rana, Syed Quadri,Lorenzo FalchiJOURNAL OF CLINICAL ONCOLOGY(2023)引用 0|浏览12暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要